[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bariatric-surgery-candidate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bariatric-surgery-candidate":613},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,62,0,25,[9,40,75,96,117,141,164,191,217,240,262,283,308,328,352,373,397,418,442,467,495,516,539,560,591],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100427857",false,"NCT04851470","Periodontal Assessment of a Bariatric Care Population","Periodontal Assessment of a Bariatric Care Population, Clinical, Genetic and Microbiological Characteristics. A Cross-sectional Study.","Bariatric","Inclusion Criteria:\n\nEach subject must meet all of the following inclusion criteria to be enrolled in the study:\n\n1. Subject must be over 18 years of age.\n2. Subject must have a BMI of higher or equal to 30 kg\u002F m2\n3. Subject must have voluntarily given written informed consent.\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria are not to be enrolled in the study:\n\n1. Subject is currently involved in other research involving the use of antibiotics or novel or unknown medications.\n2. Self-reported pregnancy.\n3. Subject is on chronic treatment (i.e., two weeks or more) with specific medications known to affect periodontal status (phenytoin or cyclosporine) within one month of baseline visit.\n4. Subject knowingly has HIV or Viral Hepatitis.\n5. Patients are completely edentulous.\n6. Subject with uncontrolled systemic illnesses.\n7. Subject is not capable to give informed consent.\n8. Subjects on chronic antibiotic therapy (ie two weeks or more in the previous month).","ALL","18 Years",{"count":20,"type":21},394,"ESTIMATED","OBSERVATIONAL","Our primary aim is to investigate the prevalence and severity of Periodonotal Disease (PD) in a population of obese patients.\n\nOur secondary objectives are to:\n\nInvestigate inflammatory biomarkers that have been associated with PD in the saliva of obese patients.\n\nInvestigate the association of FTO gene (Obesity) polymorphisms with the prevalence of PD in this population.\n\nInvestigate and describe the subgingival microbial flora in obese patients with PD from subgingival dental plaque samples as well as the salivary samples.",[25,26],"Bariatric Surgery Candidate","Obesity","RECRUITING","2026-07-01",{"date":30,"type":31},"2026-07-02","ACTUAL",{"date":33,"type":31},"2014-01-31",{"date":35,"type":21},"2027-12-31",{"name":37,"class":38},"Queen Mary University of London","OTHER",4,{"id":41,"slug":4,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100232937","NCT02310178","Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery","BAREVAL","Inclusion Criteria:\n\n* Only be considered in patients operated and followed at CHU Montpellier with bariatric surgery\n* Patients treated by bariatric surgery on CHU Montpellier\n* Agreed to participate to the study by signing an informed consent\n* Eligible to health insurance\n\nExclusion Criteria:\n\n* Unable to follow the patient in the long term (foreign patients, surgical use ...)\n* Inability to follow in the long run","15 Years",{"count":48,"type":21},750,"INTERVENTIONAL",[51],"NA","The aim of this cohort is to evaluate the follow-up of morbidly obese patients treated by several types of bariatric procedures. In addition, this study could lead to the development of clinical trials on assessment of the bariatric surgery impact.",[54,25],"Obesity, Morbid",[56,57,58,59,60,61,62,63,64],"weight loss","sleeve gastrectomy","gastric bypass","gastric banding","bariatric procedures","cohort","morbid obesity","medical and economical impact","severe obesity","2026-06-17",{"date":67,"type":31},"2026-06-22",{"date":69,"type":31},"2012-05-21",{"date":71,"type":21},"2028-12",{"name":73,"class":38},"University Hospital, Montpellier",1,{"id":76,"slug":4,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":49,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":74},"100480091","NCT05531474","Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial","BRAVE","Inclusion Criteria:\n\n1. Body mass index ≥30 kg\u002Fm2; OR BMI ≥30 kg\u002Fm2 to 34.9 kg\u002Fm2 and have type 2 diabetes or are \\>55 years of age\n2. Age ≥18 years\n3. High-risk CVD, defined as the presence of any one of the following:\n\n   1. High-risk coronary artery disease (CAD) (i.e., history of MI, percutaneous coronary intervention, coronary artery bypass grafting, or stenoses ≥ 50% in 2 or more major coronary arteries)\n   2. Left ventricular ejection fraction (LVEF) \\< 40%\n   3. Heart failure with preserved ejection fraction (LVEF \\> 40%) and either HF hospitalization in the last 2-years or N-terminal pro b-type natriuretic peptide (NT-proBNP) \\> 300 pg\u002Fml or BNP \\> 100 pg\u002Fml in the past 12 months\n   4. Documented atrial fibrillation (AF) with CHA2DS2-VASc ≥2 stroke risk score\n   5. History of any stroke\n   6. Documented peripheral arterial disease (PAD) (i.e., peripheral revascularization of the iliac, infra-inguinal or carotid arteries; limb or foot amputation for arterial vascular disease; or ≥50% carotid or peripheral artery stenosis)\n\nExclusion Criteria:\n\n1. Hospital admission for HF, myocardial infarction, stroke or coronary revascularization within 30 days of randomization\n2. Percutaneous coronary intervention with a drug eluting stent within 90 days of randomization.\n3. Pregnancy\n4. Contraindication to bariatric surgery\n5. Prior bariatric surgery, other than gastric banding\n6. Life expectancy \\<2 years from non-cardiovascular causes\n7. Inability to provide informed consent",{"count":82,"type":21},700,[51],"The primary objective of this study is to evaluate if, in patients with severe obesity (body mass index (BMI) ≥30 kg\u002Fm2) and high-risk cardiovascular disease (CVD), bariatric surgery compared to medical weight management (MWM) safely reduces the risk of major cardiovascular events. The cost-effectiveness of bariatric surgery will also be examined. Separate sub-studies will be performed to examine the relationship between bariatric surgery and mental health and cognition (BRAVE-Mind), cardiac structure and function, genomics, proteomics and metabolomics.",[86,25],"Cardiovascular Complication","2026-05-25",{"date":89,"type":31},"2026-05-28",{"date":91,"type":31},"2020-11-02",{"date":93,"type":21},"2027-07-01",{"name":95,"class":38},"Population Health Research Institute",{"id":97,"slug":4,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":39},"100325442","NCT03517072","Determinants of the Long-Term Success of Bariatric Surgery","Determinants of the Long-Term Success of Bariatric Surgery \"- Multicenter Regional Observational Study: Regional Multicentre Prospective Study","PRECOS","Inclusion Criteria:\n\n* Patients who received bariatric surgery 5 years ago.\n\nExclusion Criteria:\n\n* Refusal to participate in the study,\n* Unable to receive informed information,\n* Unable to participate in the study",{"count":104,"type":21},1000,"The management of obesity is based on a multidisciplinary approach and justifies the use of surgery in patients with the most severe forms. Surgery for obesity or bariatric surgery generally allows rapid and significant weight loss however it is associated with significant risks, and its long-term results remain heterogeneous and unpredictable. Long-term data will clarify the role of different types of bariatric surgery in surgical strategy, improve patient information and identify predictors of failure in order to provide personalised and tailored surgery for each candidate .",[107,25],"Morbid Obesity","2026-05-20",{"date":110,"type":31},"2026-05-22",{"date":112,"type":31},"2018-07-31",{"date":114,"type":21},"2027-01",{"name":116,"class":38},"University Hospital, Lille",{"id":118,"slug":4,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":49,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100636747","NCT07569705","Effect of Transcutaneous Electrical Nerve Stimulation on PODD in Bariatric Surgery Patients","Effect of Transcutaneous Electrical Nerve Stimulation on Postoperative Diaphragmatic Dysfunction in Morbidly Obese Patients Undergoing Bariatric Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Body mass index \\> 40 kg\u002Fm2\n* ASA II\n\nExclusion Criteria:\n\n* Limited diaphragmatic ultrasound views\n* Patient with pulmonary diseases (COPD, bronchial asthma, and interstitial fibrosis)\n* Patient refusal","20 Years","60 Years",{"count":126,"type":21},70,[51],"Researchers aim to evaluate impact of transcutaneous electric nerve stimulator on the incidence of postoperative diaphragmatic dysfunction in patients living with obesity undergoing bariatric surgery",[130,25],"Bariatric Surgery",[15,132],"Diaphragmatic dysfunction","2026-05-17",{"date":108,"type":31},{"date":133,"type":31},{"date":137,"type":21},"2026-08-30",{"name":139,"class":38},"Cairo University",2,{"id":142,"slug":4,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":49,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":74},"100407843","NCT04590690","Gut Microbiome and Sex as Risk Factors for Kidney Stones After Bariatric Surgery","Inclusion Criteria:\n\n* Participants without history of stone disease, family history of stone disease\n* Participants pre-bariatric surgery who are approved and planned for surgery in the Bariatric Surgery Center at University of Chicago Medicine.\n\nExclusion Criteria:\n\n* Patients with primary renal diseases or renal impairment (eGFR \\\u003C 90)\n* Patients with known bladder voiding problems\n* Patients with 25-vitamine D deficiency, as defined by level \\\u003C 25ng\u002FmL","130 Years",{"count":148,"type":21},28,[51],"This is a single-center study that aims to better understand how diet and sex affect the risk of kidney stones in people who have had gastric bypass surgery. Subjects will be asked to follow a special (clinic-provided) diet for six days and come to a research clinic for 3 study visits.",[25],[153,154],"bariatric surgery","kidney stones","2026-05-08",{"date":157,"type":31},"2026-05-11",{"date":159,"type":31},"2020-11-01",{"date":161,"type":21},"2027-05-01",{"name":163,"class":38},"University of Chicago",{"id":165,"slug":4,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":74},"100489222","NCT05650307","CV Imaging of Metabolic Interventions","Cardiovascular Imaging to Assess Responses to Metabolic Interventions","CIRCMeta","Inclusion Criteria:\n\n* Age \\> 18 years of age\n* Provision of written informed consent\n* For bariatric surgery group, obesity (BMI\\>\u002F=30 kg\u002Fm2) and non-obese (BMI \\\u003C30 kg\u002Fm2; for control group)\n* For cardiac rehabilitation group, symptomatic cardiovascular disease for patients and no signs of cardiovascular disease for healthy controls\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Contraindication to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g. dementia or cognitive disability)",true,{"count":173,"type":21},150,"Cardiovascular disease is the leading cause of death worldwide. It is becoming clearer that heart failure (HF) is closely associated with body's metabolism. Even before the heart becomes weaker, it responds to the stresses by changing the fuels it burns, which results in a reduction in the heart's metabolic efficiency that worsens the heart's condition. Since the heart burns so much fuel and consumes fats and carbohydrates along with other available substrates, any changes in its metabolic efficiency could impact metabolism throughout the body. Specifically, HF is characterized by limited flexibility in substrate utilization leading to an overall energetic deficit. Such energetic deficit is associated with progressive remodeling and alter cardiac hemodynamics. For example, obesity is a widely known risk factor for cardiovascular disease likely lie in how the heart handles energy (substrate utilization and energetics). One commonly recommended treatment for cardiovascular disease, especially coronary artery disease (CAD) or congestive heart failure (CHF), is cardiac rehabilitation. Cardiac rehabilitation for symptomatic cardiovascular disease has been shown to promote a healthy lifestyle, improve physical health and reduce cardiovascular death iii with an apparent dose-dependent response. Participation results in a reduced risk of hospitalization and revascularization procedures, and improved functional status in randomized controlled trials. Thus, cardiac rehabilitation is recommended for individuals with symptomatic CAD or CHF by the American College of Cardiology and American Heart Association. In addition, exercise training in preclinical animal models mirroring the exercise component of cardiac rehabilitation routines have shown increased myocardial regeneration and cardioprotective molecular effects ameliorating adverse myocardial remodeling. Despite these benefits, there is vast heterogeneity in the efficiency of cardiac rehabilitation on the individual level with large variances in improved exercise capacity and cardiac function recovery. Personalization of cardiac rehabilitation necessitates a non-invasive approach to monitor the direct beneficial effects on the heart and more ideally, predict efficacy at baseline. Taken together, understanding how metabolic interventions including bariatric surgery and cardiac rehabilitation change myocardial structure and function is critical for the prevention, diagnosis and prognosis for patients with cardiovascular diseases.\n\nAdvanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Our team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In collaboration with cardiologists at Cleveland Clinic, the investigators aim to study how myocardial microstructure revealed by cardiac MRI changes cardiovascular disease patient population before and after metabolic interventions.",[25,176,177],"Heart Failure","Cardiovascular Diseases",[179,180,181,182,130],"MRI","Exercise","Weight loss","Cardiac Rehabilitation","2026-05-06",{"date":155,"type":31},{"date":186,"type":31},"2022-09-09",{"date":188,"type":21},"2027-09-09",{"name":190,"class":38},"The Cleveland Clinic",{"id":192,"slug":4,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":49,"phases":199,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":74},"100636688","NCT07568938","Evaluation of the Stress Response in Anesthesia Use Inhalation Anesthetic (Desflurane) Versus TIVA for Bariatric Surgery","Evaluation of the Stress Response in Anesthesia Use Inhalation Anesthetic (Desflurane) Versus TIVA TCI ELEVELD Model for Bariatric Surgery","Inclusion Criteria:\n\n* Signed Informed Consent\n* ASA II-III\n* Morbid obesity confirmed diagnosis and approval for surgical treatment\n* Laparoscopic sleeve gastrectomy (LSG) or Gastric By pass (R-Y By pass \u002FSASI\u002FSADI AND one anastomosis by pass )\n* Preop respiratrory assessment conducted\n* Adequate organ and bone marrow function\n\nExclusion Criteria:\n\n* Patients declining or withdrawing consent\n* Patients unsuitabe with regards to compliance to treatment, according to the researcher's assessment\n* Bradycardia, AV block, , postural hypotension\n* QTcF\\>470msec\n* Known allergy or hypersensitiity to any of the medications administered\n* Stop-BANG score \\>6\n* Intraoperative administration of more than 8mg of prednisolone or equivalent\n* Patients who have received corticosteroids for durations \\>3 weeks at any point in their lifetime\n* Participation in other clinical trial for experimental product administered post operatively\n* Diagnosis of depression","65 Years",{"count":126,"type":21},[51],"The goal of this clinical trial is to compare the effects of Opioid Free Anesthesia (OFA) with and without volatile anesthetics (in this case desflurane) in patients undergoing bariatric surgery. The main question it aims to answer :\n\n-Will there be a difference in the perioperative stress between patients receiving OFA with and without desflurane?\n\nParticipants will undergoing sleeve gastrectomy or gastric by pass, will be administered OFA with and without desflurane and blood tests (cortisole, ACTH,dopamine, PRL, adrenaline, noradrenaline, lactate) will be collected perioperatively to compare stress in the two groups.",[202,25,203,26],"Opioid Use","TCI Eleveld",[107,205,206,207,130,208],"Opioid Free Anesthesia","Nociception Level","Analgesia","Eleveld Model TCI","2026-05-01",{"date":183,"type":31},{"date":212,"type":31},"2024-01-10",{"date":214,"type":21},"2027-05-30",{"name":216,"class":38},"G.Gennimatas General Hospital",{"id":218,"slug":4,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":49,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":74},"100497096","NCT05752799","Evaluation of the Stress Response in Bariatric Surgery With and Without the Use of Opioids","Inclusion Criteria:\n\n* Age \\>18y and \\\u003C75y\n* morbid obesity confirmed diagnosis\n* American Society of Anesthesiologists (ASA) II-III\n* elective laparoscopic sleeve gastrectomy surgery\n* signed informed consent\n\nExclusion Criteria:\n\n* bradycardia, bundle branch block, hypotension, postural hypotension\n* obstructive sleep apnoea\n* history of depression\n* chronic corticosteroid use or intraoperative administration of more than 8mg of prednisolone or equivalent\n* refusal to participate","75 Years",{"count":126,"type":21},[51],"The goal of this clinical trial is to compare Opioid Free and Opioid Based Anaesthesia in patients undergoing sleeve gastrectomy. The main questions it aims to answer are:\n\n* Will the total dose of intraoperative opioid be reduced?\n* Will there be difference in pain scores between groups? Participants will be managed with the Nociceptive Level Index algorithm to guide intraoperative analgesia.\n\nThe Opioid Free Anaesthesia Group will be administered the Multimix infusion (Magnesium sulfate, dexmedetomidine, ketamine). The Opioid Based Anaesthesia Group will receive fentanyl as a bolus dose and remifentanil infusion.\n\nRescue fentanyl bolused will be injected as appropriate according to nociceptive level (NOL) values.",[227,25],"Opioid Use, Unspecified",[62,229,230,231,153],"opioid free anaesthesia","nociception level","analgesia","2026-04-25",{"date":234,"type":31},"2026-04-28",{"date":236,"type":31},"2023-01-01",{"date":238,"type":21},"2027-06-01",{"name":216,"class":38},{"id":241,"slug":4,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":74},"100400424","NCT04494048","Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry","EBT","Inclusion Criteria:\n\n* Any patient who is considering undergoing EBT for weight loss within 6 months, or has undergone clinically indicated EBT for weight loss within the past 6 months\n* Above or equal to 18 years of age.\n\nExclusion Criteria:\n\n* Any patient who has not undergone or will undergo EBT for weight loss\n* Below 18 years of age.","89 Years",{"count":248,"type":21},9999,"The purpose of this registry study is to collect data through medical chart review and in patient visits on the efficacy and safety of various Endoscopic Bariatric therapies (EBTs). This is a retrospective and prospective, observational, medical chart review study for at least 6 standard of care visits up to 1 years after a subject consents for study participation.",[26,251,252,25],"Weight Loss","Gastro Esophageal Reflux","2026-04-21",{"date":255,"type":31},"2026-04-23",{"date":257,"type":31},"2016-04-05",{"date":259,"type":21},"2035-10-31",{"name":261,"class":38},"Weill Medical College of Cornell University",{"id":263,"slug":4,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":49,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":74},"100633326","NCT07525232","Stepwise PEEP vs Sustained Inflation in Bariatric Surgery Patients","Comparison of Stepwise PEEP vs Sustained Inflation Recruitment Maneuvers on Postoperative Oxygenation and Atelectasis in Bariatric Surgery Patients","Inclusion Criteria:\n\n1. Anesthesiologists (ASA) physical status II, of either sex Age ≥18 y.\n2. Undergoing laparoscopic bariatric surgeries; sleeve gastrectomy, mini gastric bypass\n3. BMI (35-60)\n\nExclusion Criteria:\n\n1. Pre-existing severe pulmonary disease\n2. Baseline hypoxemia SpO₂ \\\u003C92% on room air\n3. History of barotrauma\n4. Previous pneumothorax\n5. Known pulmonary bullae or emphysematous blebs",{"count":269,"type":21},100,[51],"Male and female patients Undergoing laparoscopic bariatric surgeries will be subjected for lung recruitment at end of surgery before emergence from anesthesia by two different methods . to evaluate which might be safer and more effective",[273,25],"Recruitment","2026-04-07",{"date":276,"type":31},"2026-04-13",{"date":278,"type":31},"2026-03-19",{"date":280,"type":21},"2026-11-01",{"name":282,"class":38},"Ain Shams University",{"id":284,"slug":4,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":171,"sex":17,"minAge":18,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":49,"phases":292,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":140},"100538599","NCT06292936","RemI for Post-Bariatric Surgery Weight Regain","Evaluation of a Remotely-Delivered Behavioral Intervention for Post-Bariatric Surgery Weight Regain","Inclusion Criteria:\n\n* Men and women\n* Ages 18-70 years old\n* Weight regain of at least 5% from lowest postoperative weight\n* Body mass index (BMI) 25 or above\n* Underwent gastric bypass or sleeve gastrectomy within 6 to 48 months prior to enrollment\n* Ability to give consent\n* Ability to speak, write, and understand English\n\nExclusion Criteria:\n\n* Long-term treatment with oral steroids\n* Current use of weight loss medication (OTC or prescription)\n* Current pregnancy, plan to become pregnant within 12 months, lactation within the past 6 months\n* Psychiatric hospitalization in the past 6 months\n* Documented or self-reported psychiatric diagnosis that would interfere with adherence to the study protocol or acute suicidality\n* Self-report of alcohol or substance abuse within the past 12 months\n* Current, self-reported use of tobacco products\n* Weight loss \\> 10 lbs in the past 3 month\n* History of more than one bariatric procedure\n* Inability to walk at least one city block without assistance","70 Years",{"count":291,"type":21},200,[51],"The goal of this clinical trial is to test the effectiveness of remotely-delivered interventions (utilizing acceptance-based behavioral treatment skills (ABTi)) amongst bariatric surgery populations who are experiencing weight regain postoperatively (\\> 5% from their lowest postoperative weight and after postoperative Month 6). Investigators aim to evaluate ABTi's efficacy for reversing weight regain and its effect on targeted weight control behaviors and weight-related comorbidities by comparing participants randomly assigned ABTi (n = 100) to those assigned to a Control group that also receives brief phone calls but that focus on reiterating instruction on the dietary and behavioral changes required of surgery and initially taught preoperatively (C, n = 100).\n\nThe main research aims are:\n\n1. To compare changes in body weight over 12 months in 200 bariatric patients who have regained \\> 5% of their weight and are randomly assigned to ABTi or Control.\n2. To compare changes in eating behaviors (i.e., caloric intake, frequency of maladaptive eating behaviors), physical activity, and weight-related comorbidities (i.e., biomarkers of diabetes, hypertension) over 12 months in the two groups.\n3. Exploratory - To test ABTi's theoretical mechanisms of action, including a) effects of theory-based active ingredients (i.e., acceptance, defusion, values clarity, mindfulness) on weight outcomes and b) changes in impact of internal states (i.e., hunger, cravings) on eating behavior.",[26,25],[296,297,298],"Acceptance-Based Behavioral Therapy","Postoperative Outcomes","Weight Regain","2026-04-02",{"date":301,"type":31},"2026-04-03",{"date":303,"type":31},"2024-04-15",{"date":305,"type":21},"2028-05-31",{"name":307,"class":38},"Temple University",{"id":309,"slug":4,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":246,"enrollmentInfo":313,"targetDuration":4,"studyType":49,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":318,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":74},"100622597","NCT07385690","Xpan Non-Inferiority Study","Inclusion Criteria:\n\n* Individuals scheduled for the following procedures:\n\n  * Sleeve Gastrectomy\n  * Bypass\n  * Revision \\& other bariatric procedures\n  * Robotic procedures\n  * Bariatric patients\n\nExclusion Criteria:\n\n* Any individual not scheduled for the above procedure and\u002For does not meet the age requirments.",{"count":314,"type":21},35,[51],"A trocar is a surgical instrument with a sharp point and tube and is used to create endoscopic access in the abdomen or chest where endoscopic instruments can be entered \\& used in minimally invasive surgical procedures. Xpan has created an FDA Cleared radially dilating trocar (RDT) that is inserted at 3mm and can be expanded to 5mm or 12mm during surgery. The purpose of this research protocol is to demonstrate that a new FDA Cleared Xpan® radially dilating trocar (RDT) system is at least, just as effective as the existing RDT trocar systems. The procedure will be performed using a radially dilating trocar that is inserted at 3mm and can be expanded to 5mm or 12mm during surgery.",[25],"NOT_YET_RECRUITING","2026-02-02",{"date":321,"type":31},"2026-02-04",{"date":323,"type":21},"2026-02",{"date":325,"type":21},"2027-02",{"name":327,"class":38},"West Virginia University",{"id":329,"slug":4,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":49,"phases":336,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":318,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":74},"100601002","NCT07104825","Autonomic Neural Blockade in Bariatric Surgery","Autonomic Neural Blockade During Sleeve Gastrectomy and Gastric Bypass: A Randomized Controlled Trial Evaluating Pain and Nausea After Bariatric Surgery","Inclusion Criteria:\n\n* Individuals able and willing to consent and participate in all study activities\n* Adults, ages 18-90\n* All patients with severe obesity undergoing laparoscopic\u002Frobotic gastric bypass or sleeve gastrectomy\n\nExclusion Criteria:\n\n* Patients taking opiates chronically\n* Patients allergic to study medications\n* Patients with any prior adverse reaction to ingredients included in the block\n* Adults unable to consent\n* Pregnant women\n* Prisoners","90 Years",{"count":291,"type":21},[51],"The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain\u002Fnausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.",[25,339,340,202],"Pain, Postoperative","Nausea and Vomiting, Postoperative",[342],"Autonomic, blockade, bariatric surgery","2026-01-27",{"date":345,"type":31},"2026-01-29",{"date":347,"type":21},"2026-03",{"date":349,"type":21},"2027-12",{"name":351,"class":38},"Endeavor Health",{"id":353,"slug":4,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":49,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":74},"100492660","NCT05695040","Evaluation of the Implementation of a Diet Workshop on the 15th Postoperative Day Following Bariatric Surgery","Evaluation of the Implementation of a Diet Workshop on the 15th Postoperative Day Following Bariatric Surgery on the Protein Intake of the Patient","ADAPT","Inclusion Criteria:\n\n* Male or female\n* Over 18 years of age\n* Scheduled for bariatric surgery such as sleeve gastrectomy or bypass surgery.\n* Able to give informed consent to participate in the research.\n* Enrolled in a Social Security system.\n\nExclusion Criteria:\n\n* Inability to travel to participate in the workshop.\n* Patients with a diet excluding animal proteins (vegetarians, vegans).\n* Pregnant and lactating women.\n* Inability to comply with protocol recommendations.\n* Incapacitated patients.\n* Major deprived of liberty\n* Refusal to participate.",{"count":360,"type":21},88,[51],"The objective of the study was to improve protein intake after the implementation of a dietary workshop performed on the 15th postoperative day following bariatric surgery.",[25],"2025-12-10",{"date":366,"type":31},"2025-12-18",{"date":368,"type":31},"2023-12-08",{"date":370,"type":21},"2028-03",{"name":372,"class":38},"University Hospital, Clermont-Ferrand",{"id":374,"slug":4,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":171,"sex":17,"minAge":18,"maxAge":289,"enrollmentInfo":380,"targetDuration":4,"studyType":49,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":74},"100548747","NCT06425016","Effects of Assisted Robotic vs Laparoscopic Sleeve Gastrectomy","Effects of Assisted Robotic vs Laparoscopic Sleeve Gastrectomy (EARLY): A Randomized Controlled Trial on Early Postoperative Pain","EARLY","Inclusion Criteria:\n\n* All patients eligible to undergo a SG based on the current National Institute of Health (NIH) patient selection guidelines. Patients should be able to give consent, be deemed medically cleared to undergo elective surgery, and tolerate general anesthesia.\n\nExclusion Criteria:\n\n* patients with previous bariatric surgeries, emergency surgeries, with chronic opioid use (daily use of opioids for at least 3 months), and those who are not able to sign the written consent form.",{"count":381,"type":21},91,[51],"This will be a prospective, obesity-registry based, single-blind randomized controlled trial with a 1:1 allocation ratio. Specific inclusion criteria are all patients eligible to undergo a Laparoscopic sleeve gastrectomy (LSG) based on the current National Institute of Health (NIH) patient selection guidelines. Patients should be able to give consent, be deemed medically-cleared to undergo elective surgery, and tolerate general anesthesia. All enrollments and surgeries in this study will take place at the Cleveland Clinic Bariatric and Metabolic Institute. The study will consist of 2 interventions: laparoscopic sleeve gastrectomy (LSG) or robotic sleeve gastrectomy (RSG). The primary objective is early postoperative pain, but also surgeon ergonomics and patient quality of life will be compared. Additional outcomes include 30-day perioperative results, minor and major morbidities, serious adverse events, resolution of medical comorbidities, and weight loss in percent of excess weight lost (%EWL) at one year.",[385,386,387,26,25,388],"Post Operative Pain","Laparoscopic Sleeve Gastrectomy","Robotic Sleeve Gastrectomy","Quality of Life","2025-12-03",{"date":364,"type":31},{"date":392,"type":31},"2024-07-17",{"date":394,"type":21},"2027-04-30",{"name":396,"class":38},"Ricard Corcelles",{"id":398,"slug":4,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":403,"targetDuration":4,"studyType":49,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":74},"100239121","NCT02390973","Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)","REMISSION","Inclusion Criteria:\n\n* BMI ≥ 35\n* type 2 diabetes\n* HbA1c ≥ 6,5 % or fasting glycemia ≥7mmol\u002Fl or non-fasting glycemia ≥11mmol\u002Fl\n* able to consent\n\nExclusion Criteria:\n\n* pregnancy\n* past esophageal, gastric or bariatric surgery\n* irritable bowel, unexplained intermittent vomiting, severe abdominal pain, chronic diarrhea or constipation\n* history of gastric or duodenal ulcers\n* pre-operatory hypoalbuminemy\n* history of renal, hepatic, cardiac or pulmonary severe disease\n* taken of corticosteroid in the last month\n* evidence of psycological problem that may affect the capacity to understand the project and to comply with the medical recommandations\n* history of drug use or alcool abuse in the last 12 months\n* history of gastro-intestinal inflammatory diseases",{"count":404,"type":21},408,[51],"Bariatric surgery procedures induce weight loss through restriction and\u002For malabsorption. The mechanisms underlying type 2 diabetes remission and others metabolic improvements after Roux-en-Y Gastric Bypass (RYGB), sleeve gastrectomy (SG) or biliopancreatic diversion with duodenal switch (BPD-DS) have not yet been formally studied. The investigators propose a longitudinal study with the overall objective of measuring the long-term impact of these three bariatric surgeries (RYGB, SG, BPD-DS) on metabolic, renal and cardiovascular fate in patients with type 2 diabetes. The investigators overall hypothesis is that some bariatric procedures generate hitherto unrecognized effects on many disease-related outcomes, which greatly contributes to their beneficial impact in diabetic patients. The investigators propose 3 specific aims: 1) to establish the long term effect of the three surgeries on the metabolic recovery and quality of life in groups of diabetic patients treated with insulin, hypoglycemic agents or diet; 2) to establish the long term impact of the three surgeries on renal and cardiovascular functions in subgroup of patients with these conditions; 3) to compare metabolic impact of surgeries to those of best medical care for diabetes in a non-surgical control group. For most severely obese patients, lifestyle interventions, perhaps effective in inducing short-lived weight losses, are ineffective for long-term weight loss maintenance and durable metabolic recovery. The increasing popularity of obesity surgeries calls for a better understanding of the underlying mechanisms. This is especially true and urgent when considering that knowledge on the relative impact of each procedure (i.e. SG vs. RYGB and BPD-DS) in resolving T2D is still limited. Better knowledge on each of the procedures will allow stronger scientific rationale for selecting the right surgery for the right patient and improve care for the severely obese individual.",[25,408],"Diabetes","2025-12-01",{"date":411,"type":31},"2025-12-08",{"date":413,"type":4},"2015-03",{"date":415,"type":21},"2030-03",{"name":417,"class":38},"Laval University",{"id":419,"slug":4,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":424,"maxAge":197,"enrollmentInfo":425,"targetDuration":427,"studyType":22,"phases":4,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":74},"100439338","NCT05000996","Gut Microbiota in Metabolic Surgery","The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study","Inclusion Criteria:\n\n* Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical Center\n* Have a history of type 2 diabetes, hypertension, or dyslipidemia\n* Be able and willing to provide personal information and biological samples needed for the study\n\nExclusion Criteria:\n\n* Prior gastric operations\n* A history of coronary artery disease, stroke, heart failure, HIV infection, or untreated viral hepatitis\n* Chemotherapy or radiotherapy for cancer within 2 years\n* Current inflammatory bowel disease or celiac disease\n* Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2 months","21 Years",{"count":426,"type":21},300,"10 Years","Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes. Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its relation to cardiometabolic health after surgery are limited. Furthermore, few studies have included African Americans, a population with high rates of cardiometabolic diseases. The investigators aim to fill these research gaps by establishing a longitudinal, observational study of metabolic surgery patients and applying multi-omics to identify stool, blood, and\u002For tissue microbial features related to post-surgery cardiometabolic outcomes. In the current study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at Vanderbilt University Medical Center and follow them for up to 10 years after surgery. Fasting blood and stool samples will be collected at pre-surgery and 3-month, 1-year, 2-year, and 3-year post-surgery clinical visits. Tissue samples (e.g., biopsies of the liver and adipose and remnants of the stomach) will be collected during operation. Meanwhile, participants will complete a REDCap survey at baseline and 1-year, 2-year, and 3-year post-surgery. Participants' electronic medical records will be used to obtain additional information and facilitate long-term follow-up. The investigators will evaluate pre- to post-surgery changes in the fecal microbiome and fecal and blood levels of metabolites and proteins and the associations of microbiome, metabolites, and proteins with cardiometabolic improvements after surgery. This study will advance our understanding of the role of gut microbiota in metabolic surgery, which may translate into novel approaches to identify and treat obese patients for better cardiometabolic health.",[25,177,430,431,432,107],"Type 2 Diabetes","Dyslipidemias","Hypertension","2025-11-02",{"date":435,"type":31},"2025-11-04",{"date":437,"type":31},"2021-08-19",{"date":439,"type":21},"2035-01-01",{"name":441,"class":38},"Vanderbilt University Medical Center",{"id":443,"slug":4,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":448,"targetDuration":4,"studyType":49,"phases":449,"briefSummary":450,"conditions":451,"keywords":454,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":466},"100434815","NCT04942093","NUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery","NUTRACOB","Inclusion Criteria:\n\n* Patient eligible for bariatric surgery (according to HAS criteria) whose sleeve gastrectomy is scheduled\n* Patient with morbid obesity (BMI ≥ 40)\n* Age ≥ 18 years and ≤ 65 years\n* Haemoglobinemia ≥ 12 g\u002FdL in men and ≥ 11 g\u002FdL in women\n* Patient speaking and understanding French\n* Adult having read and understood the information letter and signed the consent form\n* Woman of childbearing age with effective \u002F very effective contraception (Cf. CTFG) (estrogen-progestin or intrauterine device or tubal ligation) prior to surgery and a negative -HCG blood pregnancy test at inclusion, for the duration of the study\n* Postmenopausal woman: confirmatory diagnosis (non-medically induced amenorrhoea for at least 12 months prior to the inclusion visit)\n* Patient affiliated with, or beneficiary of a social security (health insurance) category\n\nExclusion Criteria:\n\n* Contraindication to bariatric surgery detected during the preoperative assessment\n* Medical contraindication to a restrictive diet\n* Type I or II insulin-requiring diabetes\n* Severe renal insufficiency defined by a blood filtration rate \\\u003C 30 mL\u002Fmin\n* Person wearing a pacemaker or any other implant with the same functions (cochlear implant, bladder battery, etc.)\n* Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection \u002F sub-guardianship or curatorship\n* A history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent him\u002Fher from giving informed consent",{"count":291,"type":21},[51],"Obesity is a major public health problem and is constantly on the rise. Therapeutic approaches based on dietary advice, physical activity and the management of psychological difficulties are not always sufficient to achieve a lasting weight reduction.\n\nBariatric surgery (or obesity surgery), accompanied by therapeutic education and adequate medical and dietary monitoring, can lead to significant and lasting weight loss. It is indicated as a second-line treatment for patients who have failed medical treatment, whose BMI is greater than or equal to 40 or whose BMI is greater than or equal to 35 with comorbidities (type 2 diabetes, arterial hypertension, obstructive sleep apnoea-hypopnoea syndrome, severe joint disorders).\n\nThe surgeon may be very bothered by the intra-abdominal fat mass and especially by steatotic hepatomegaly (increase in the size of the liver and its fat load).\n\nFaced with this problem, various preoperative strategies such as the placement of an intra gastric balloon have been tried to decrease the size of the liver but a systematic review from 2016 indicates that a low calorie diet is preferable. Preoperative weight loss can reduce fat load and liver volume very rapidly. This meta-analysis shows that all low-calorie, high-protein diets are effective and that the optimal duration (4 weeks), compliance and tolerance are important factors for success.",[452,453,25],"Diet, Healthy","Obesity, Visceral",[455,456,153],"diet","obesity","2025-09-16",{"date":459,"type":31},"2025-09-22",{"date":461,"type":31},"2023-10-09",{"date":463,"type":21},"2027-03-20",{"name":465,"class":38},"University Hospital, Rouen",3,{"id":468,"slug":4,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":171,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":474,"targetDuration":4,"studyType":49,"phases":476,"briefSummary":477,"conditions":478,"keywords":481,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":74},"100486030","NCT05608772","Conversion to SADI-S, RYGB or OAGB After Failed Sleeve","Conversion of Failed Sleeve Gastrectomy Due to Weight Regain to SADI-S, RYGB or OAGB","RCTresleeve","Inclusion Criteria:\n\n* Undergone primary laparoscopic sleeve gastrectomy in the past\n* Weight regain\n\n  * defined as any increase in weight above the nadir as reported by the patient\n  * BMI at the time of revisional surgery was around 45 kg\u002Fm2\n  * weight regain was defined as an increase in BMI after bariatric surgery to exceed 35\n* With or without Gastroesophageal reflux disease (GERD) grade A and B o Patients with grade C or higher GERD, according to the Los Angeles (LA) classification \\[7\\] will be excluded from the study\n\nExclusion Criteria:\n\n* Didn't follow preoperative consultation\n* Cannot give of sign informed consent",{"count":475,"type":21},234,[51],"Assess what revisional surgery is superior and provides the best weight loss after primary LSG. What is the occurrence of complications and the nutritional laboratory status? And if the resolution and \u002For improvement of associated medical problems after the weight loss will occur.",[251,25,479,480],"Comorbidities and Coexisting Conditions","Nutrient Deficiency",[482,483,484,485],"RYGB","OAGB","SADI-S","Sleeve gastrectomy","2025-09-10",{"date":457,"type":31},{"date":489,"type":31},"2023-03-15",{"date":491,"type":21},"2028-04-15",{"name":493,"class":494},"General Committee of Teaching Hospitals and Institutes, Egypt","OTHER_GOV",{"id":496,"slug":4,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":334,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":318,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":4},"100606406","NCT07175142","Halitosis, Sleep and Mental Health in Bariatric Surgery Candidates","Assessment of Psychological Distress, Sleep Quality, and Halitosis in Patients With Obesity: Protocol for an Observational Study in the Preoperative Period of Bariatric Surgery","Inclusion Criteria:\n\n* Adults ≥18 years with a diagnosis of obesity\n* Referred for psychological care at the \"Rosinha Viegas\" Interprofessional Outpatient Clinic during preoperative preparation for bariatric surgery (Brazilian public health system - SUS)\n\nExclusion Criteria:\n\n* Individuals with cognitive or neurological limitations that impair understanding or participation in the assessment procedures\n\nIndividuals who refuse or withdraw consent",{"count":502,"type":21},110,"This study aims to evaluate psychological distress, sleep quality, and halitosis in obese patients during the preoperative period of bariatric surgery. A total of 110 adults will be assessed using validated questionnaires and a portable halitosis detector. The results may contribute to improving strategies for comprehensive care in this population.",[26,25,505,506,507],"Halitosis","Sleep Disorder","Stress, Psychological","2025-09-09",{"date":457,"type":31},{"date":511,"type":21},"2025-10-01",{"date":513,"type":21},"2026-06-30",{"name":515,"class":38},"University of Nove de Julho",{"id":517,"slug":4,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":171,"sex":17,"minAge":424,"maxAge":197,"enrollmentInfo":522,"targetDuration":4,"studyType":49,"phases":524,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":140},"100551527","NCT06461247","Compliance With Standard Care vs Ready to Eat Meals Prior to Bariatric Surgery","Compliance With Standard Care vs Ready to Eat Meals Prior to Bariatric Surgery - a Randomised Controlled Trial","Inclusion Criteria:\n\n* Adults aged 21 to 65 years old\n* Scheduled for bariatric surgery at least 1 month prior\n* BMI ≥ 27.5 kg\u002Fm2 (with type 2 diabetes mellitus or metabolic syndrome)\n* Owns a smart phone with data plan\n* English speaking\n\nExclusion Criteria:\n\n* Cognitive impairment.\n* Hypothyroidism\n* Chronic kidney disease\n* Hypothyroidism\n* Depression with ongoing psychology follow up\n* Type 1 diabetes\n* Liver Cirrhosis\n* Pregnancy\n* Heart Failure\n* Active cancer or in remission for less than 5 years\n* Vegetarian\n* Observing the fast during the month of Ramadan\n* Undergoing treatment with anti obesity medications (eg: Phentermine\u002FOrlistat\u002FContrave\u002FGLP-1 analogues etc)",{"count":523,"type":21},140,[51],"Currently, a ketosis-inducing programme, usually a liquid meal replacement, is the standard of care for pre-operative dietary management. However, compliance with liduiqd meal replacement is challenging primarily due to individual taste preferences, limited variety, having to take a liquid diet, lifestyle factors, and other obstacles. Therefore, there is a need for RTE meals to enhance patient satisfaction and compliance, ultimately resulting in improved pre-operative weight loss outcomes. Hence, this RCT study aims to determine whether Very Low Calorie Diet Ready-to-eat (VLCD RTE) meals would lead to greater compliance as measured by blood ketones and meal logging via Nutritionist Buddy app (nBuddy App) compared to standard care liquid meal replacement (Optifast) prior to bariatric surgery.",[25],[181,528,529],"Very Low Calorie Diet","Body Weight","2025-09-05",{"date":532,"type":31},"2025-09-12",{"date":534,"type":31},"2024-07-01",{"date":536,"type":21},"2026-09",{"name":538,"class":38},"National University Hospital, Singapore",{"id":540,"slug":4,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":171,"sex":17,"minAge":18,"maxAge":289,"enrollmentInfo":545,"targetDuration":4,"studyType":49,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":558,"locationsCount":74},"100555378","NCT06511310","Exercise, Brain Activity, and Weight Maintenance","Effects of Exercise Training on Brain Activity and Its Relation to Weight Maintenance and Appetite Regulation","Inclusion Criteria:\n\n* Age 18-70 years\n* Body mass index (BMI) \\>19 kg\u002Fm2 and body weight\\\u003C 250kg\n* Participants must have experienced a clinically significant weight regain, defined as over 10% of their maximum weight lost, within 1 to 5 years following their bariatric surgery. They will be asked to self-report their weight loss history. Participants must also provide the operative report from their bariatric surgery for reference.\n* In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations\n* Willing to adhere to the protocol requirements for the duration of the study\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Peripheral neuropathy with insensate feet\n* Recent blood donation within the last 2 months\n* Use of beta-blockers\n* Current pregnancy or breastfeeding\n* Active Heart or lung disease\n* Severe hypertension (systolic \\>160 mmHg or diastolic \\>90 mmHg)\n* Inability to exercise for any reason\n* Any known contraindication to exercise testing based on current ACSM guidelines\n* MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body\n* Known presence of a structural brain lesion (e.g. tumor, cortical infarct)\n* Presence of another neurologic disorder, which could impact findings (e.g. multiple sclerosis)\n* History of cardiovascular disease, stroke, congestive heart failure\n* Active hematological, renal, pulmonary or hepatic disorders\n* Active treatment for cancer\n* A history of active alcohol or substance abuse\n* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol\n* History of claustrophobia and inability to tolerate an MRI\n* Body weight \\>250kgr and largest body diameter of 70cm as there is a certain weight and diameter limit of the MRI scanner\n* Unwilling or unable to return for study visits, undergo neuropsychological testing and MRI imaging\n* Left-handedness",{"count":546,"type":21},15,[51],"This study aims to explore how HIIT influences brain function, neural and molecular pathways related to weight control, setting the stage for future obesity intervention research.",[26,550,25,551],"Weight Gain","Appetitive Behavior","2025-08-27",{"date":554,"type":31},"2025-09-04",{"date":556,"type":21},"2025-09-15",{"date":93,"type":21},{"name":559,"class":38},"Joslin Diabetes Center",{"id":561,"slug":4,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":171,"sex":17,"minAge":566,"maxAge":4,"enrollmentInfo":567,"targetDuration":568,"studyType":22,"phases":4,"briefSummary":569,"conditions":570,"keywords":578,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":74},"100287699","NCT03025074","Blood Collection Biorepository for Liver Disease Research","Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases","Inclusion Criteria:\n\n* This protocol is to establish a biobank of blood samples from individuals with or without liver diseases including viral hepatitis, liver cancer, NASH, and negative control samples.\n* Children and teenagers will be special populations considered in this protocol.\n\nExclusion Criteria:\n\n* Vulnerable populations such as adults unable to consent, infants, pregnant women or prisoners will not be considered for this research study.","7 Years",{"count":104,"type":21},"1 Day","The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.",[571,572,573,574,575,576,577,25],"Non-Alcoholic Steatohepatitis(NASH)","Hepatitis C","Hepatitis B","Fibrosis","Cirrhosis","Fatty Liver","Obesity, Childhood",[579,26,580,581,582],"Liver Disease","Hepatitis","HIV","Hepatology","2025-08-20",{"date":552,"type":31},{"date":586,"type":4},"2013-07",{"date":588,"type":21},"2099-12",{"name":590,"class":38},"State University of New York at Buffalo",{"id":592,"slug":4,"hasResults":11,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":597,"targetDuration":4,"studyType":49,"phases":599,"briefSummary":600,"conditions":601,"keywords":602,"overallStatus":318,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":611,"locationsCount":4},"100528627","NCT06163235","Efficacy of a Mobile Application and Semi-attendance Program in Bariatric Surgery","Efficacy of a Mobile Application and Semi-attendance Program in Bariatric Surgery: a Randomized Clinical Trial","Inclusion Criteria:\n\n* BMI between 35-50kg\u002Fm2\n* Bariatric surgery candidates\n\nExclusion Criteria:\n\n* Non-controlled psychiatric disorder\n* Pregnancy desire in the next 12 months\n* Do not have mobile devices (smartphone)\n* Language barrier with Spanish.",{"count":598,"type":21},72,[51],"BACKGROUND: Applications for mobile devices in patients with obesity offer a great opportunity to improve the quality of care and the monitoring of patients in bariatric surgery programs. This is especially pressing in the context of an increasing prevalence of obesity, and longer waiting lists in bariatric surgery programs.\n\nOBJECTIVES: The main objective is to evaluate the efficacy of a digital platform on mobile devices in obesity and bariatric surgery programs. Investigators will compare weight loss at 12 months after surgery in patients in the standard of care program and those in a semi-attendance program with digital support through a mobile application. As secondary objectives, it will be compared: (1) the number medical complications, the quality of life and satisfaction, physical activity, diet and attrition at 12 months after surgery. Investigators will also study the patient interaction with the platform and social networks.\n\nTRIAL DESIGN: Randomized, non-inferiority clinical trial with a 12-month follow-up.\n\nMETHODS: 72 patients will be randomized (1: 1) to standard of care program and to semi-attendance program with digital support from the bariatric surgery program waiting list. Inclusion criteria: age between 18 and 60 years, body mass index between 35-50kg\u002Fm2, candidates for the sleeve gastrectomy technique, and possession of a mobile device. Participants will be evaluated before and 12 months after surgery. Variables: anthropometric measurements, medical complications during follow-up, quality of life, diet and physical activity questionnaires. Primary endpoint: weight loss 12 months after surgery.",[26,25],[603,604,181],"Bariatric surgery","Telemedicine","2025-08-17",{"date":607,"type":31},"2025-08-21",{"date":609,"type":21},"2025-09-25",{"date":35,"type":21},{"name":612,"class":38},"Parc de Salut Mar",""]